Doximity Stock Plunges 20% on Weak Guidance, AI Costs

Shares of Doximity (NYSE: DOCS) plunged over 20% in trading on May 14, 2026, following the release of the company's quarterly earnings report. Reporting from Seeking Alpha confirmed the sharp decline was driven by forward-looking guidance that fell short of Wall Street expectations. The healthcare technology company also signaled that significant investments in artificial intelligence are beginning to pressure its profit margins, creating uncertainty about its near-term earnings power and growth trajectory.

What Drove the Weak Financial Guidance?

Doximity's guidance for the upcoming fiscal year was the primary catalyst for the sell-off. The company projected full-year revenue in a range of $550 million to $560 million. This forecast was notably below the consensus analyst estimate of $585 million, suggesting a potential slowdown in its core business.

Management attributed the conservative outlook to elongated sales cycles with its key pharmaceutical and hospital clients. These customers, who pay to advertise and connect with physicians on the Doximity platform, appear to be scrutinizing their marketing budgets more carefully. The guidance implies a year-over-year growth rate of approximately 10%, a deceleration from the 20%-plus growth investors had become accustomed to in prior years.

How Is AI Impacting Doximity's Margins?

While Doximity is positioning artificial intelligence as a long-term growth driver, the short-term financial impact is negative. The company announced plans to accelerate its spending on AI research and development to build new tools for physicians. This includes hiring specialized engineers and investing in the necessary computing infrastructure.

These investments are directly impacting profitability. Executives stated that AI-related expenses are expected to reduce adjusted EBITDA margins by approximately 250 basis points over the next fiscal year. This compression surprised investors who have historically valued Doximity for its high, software-as-a-service (SaaS) style margins, which previously exceeded 40%.

Investor Reaction and Valuation Reset

The market's reaction was swift and severe. The 20% single-day stock drop erased nearly $1 billion from Doximity's market capitalization. The move sent the stock to an 18-month low, reflecting a significant reset in investor expectations. The valuation multiple, once a premium in the health-tech sector, is now contracting as the market prices in slower growth and lower near-term profitability.

This repricing highlights a critical challenge for many technology companies. While AI presents a massive opportunity, the path to monetizing these investments is not always clear or immediate. Investors are now weighing the potential long-term benefits of Doximity's AI strategy against the certainty of lower margins and revenue deceleration in the coming quarters.

Acknowledging Competitive Risks

Doximity's moat is its vast network of over 80% of U.S. physicians, creating a powerful network effect. However, the digital health landscape is becoming increasingly competitive. A risk to the company's strategy is that the return on its substantial AI investments may not materialize as expected or may not be enough to fend off rivals.

Other platforms are also integrating AI to serve the healthcare market. If competitors develop more effective or lower-cost AI tools, Doximity could lose its edge. The company must demonstrate that its new features provide enough value to justify its premium pricing and retain engagement from both physicians and paying clients.

Q: What is Doximity's primary business model?

A: Doximity operates as a professional social network exclusively for verified medical professionals in the United States. It generates the vast majority of its revenue not from its physician members, but from pharmaceutical companies, hospitals, and health systems. These clients pay subscription fees for marketing, hiring, and telehealth solutions that allow them to connect with the platform's extensive user base of doctors, nurse practitioners, and physician assistants.

Q: What specific AI tools is Doximity developing?

A: The company is primarily focused on building generative AI tools aimed at reducing administrative burdens and physician burnout. A key product is an AI-powered assistant that helps draft and edit clinical documentation, such as patient chart notes and insurance pre-authorization letters. The goal is to save clinicians time on paperwork, allowing them to focus more on patient care, which Doximity hopes will deepen engagement with its platform.

Bottom Line

Doximity's stock has been sharply repriced as investors grapple with the dual headwinds of slowing revenue growth and the high upfront cost of AI development.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.